Duyuru • Jul 28
Nevis Brands Inc., Annual General Meeting, Sep 24, 2026 Nevis Brands Inc., Annual General Meeting, Sep 24, 2026. Location: british columbia, vancouver Canada Reported Earnings • Jul 19
First half 2026 earnings released: CA$0.002 loss per share (vs CA$0 in 1H 2025) First half 2026 results: CA$0.002 loss per share (further deteriorated from CA$0 in 1H 2025). Revenue: CA$799.0k (down 4.3% from 1H 2025). Net loss: CA$77.2k (loss widened CA$73.9k from 1H 2025). Over the last 3 years on average, earnings per share has increased by 57% per year but the company’s share price has fallen by 44% per year, which means it is significantly lagging earnings. New Risk • Apr 16
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Canadian stocks, typically moving 19% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (19% average weekly change). Market cap is less than US$10m (CA$1.36m market cap, or US$991.6k). Minor Risk Revenue is less than US$5m (CA$1.7m revenue, or US$1.2m). Reported Earnings • Mar 19
Full year 2025 earnings released: CA$0.007 loss per share (vs CA$0.009 loss in FY 2024) Full year 2025 results: CA$0.007 loss per share (improved from CA$0.009 loss in FY 2024). Revenue: CA$1.70m (up 9.4% from FY 2024). Net loss: CA$275.1k (loss narrowed 24% from FY 2024). Reported Earnings • Oct 23
Third quarter 2025 earnings released: CA$0.001 loss per share (vs CA$0.001 profit in 3Q 2024) Third quarter 2025 results: CA$0.001 loss per share (down from CA$0.001 profit in 3Q 2024). Revenue: CA$478.8k (flat on 3Q 2024). Net loss: CA$33.7k (down 221% from profit in 3Q 2024). Over the last 3 years on average, earnings per share has increased by 73% per year but the company’s share price has fallen by 13% per year, which means it is significantly lagging earnings. Reported Earnings • Jul 16
Second quarter 2025 earnings released: EPS: CA$0 (vs CA$0.002 loss in 2Q 2024) Second quarter 2025 results: EPS: CA$0 (improved from CA$0.002 loss in 2Q 2024). Revenue: CA$418.7k (down 4.1% from 2Q 2024). Net loss: CA$11.5k (loss narrowed 82% from 2Q 2024). Over the last 3 years on average, earnings per share has increased by 75% per year but the company’s share price has fallen by 28% per year, which means it is significantly lagging earnings. Duyuru • Jun 30
Nevis Brands Inc., Annual General Meeting, Aug 27, 2025 Nevis Brands Inc., Annual General Meeting, Aug 27, 2025. Location: british columbia, vancouver Canada Duyuru • Feb 21
Nevis Brands Inc. announced that it expects to receive $0.1 million in funding Nevis Brands Inc. announced that it will issue an unsecured promissory note with returning investor, John Kueber for principal amount of $100,000 on February 20, 2025. The Kueber Note carry a coupon of 10% per annum and will mature on February 15, 2026. The transaction has been approved by the shareholder board. Duyuru • Oct 27
Nevis Brands Inc. announced that it expects to receive $0.225 million in funding Nevis Brands Inc. announced a non-brokered private placement of up to 2,500,000 common shares at a price of $0.09 per share for aggregate gross proceeds of up to $225,000 on October 25, 2024. The transaction will include participation from certain insiders of the company. All securities issued in connection with the offering will be subject to a statutory hold period of four months and one day from the date of issuance. Duyuru • Jul 04
Nevis Brands Inc., Annual General Meeting, Aug 29, 2024 Nevis Brands Inc., Annual General Meeting, Aug 29, 2024. Location: british columbia, vancouver Canada Duyuru • May 10
Nevis Brands Inc Receives Necessary State Regulatory Approvals and Is Completing Production on 3 New Products to Add to Its Existing Portfolio of Products for Sale in Washington State Nevis Brands Inc. announced it has received necessary state regulatory approvals and is completing production on 3 new products to add to its existing portfolio of products for sale in Washington State. These include Major(TM) Apple Peach 100mg Shots Major(TM) Zero Cal Lemonade 100mg Shots Happy Apple (TM) 10mg Cans. These new products will be in market in May 2024 and are expected to contribute to the company's royalty revenues beginning June 2024. Washington State dispensaries currently sell over $700,000 per month of Nevis related products through licensed dispensaries. Products include Major(TM) in 9 flavors, Happy Apple(TM) 100mg bottles, Vertus(TM) a sparkling cider designed to emulate Prosecco, and Velvet Swing(TM). Nevis collects royalties on the sale of these products through its exclusive licensee in each market. The Company may also introduce these new products to licensees in other states. Nevis Brands products are currently sold in Washington, Oregon, Arizona, Ohio, Colorado, California, Missouri and Nevada. The Company is preparing for production in Michigan. Duyuru • Dec 19
Nevis Brands Inc. Announces Product Extension in Ohio Nevis Brands Inc. announced several corporate updates: Product Extension in Ohio: The Company has expanded its Major line of beverages to include a 6th flavor of Major: Atomic Apple. Production has now been completed and inventory is being sold to Ohio retailers. Product Expansion: Washington State. The Company has filed 3 new products for approval in Washington State. The products include two new beverage products and an additional edible product. Nevis will announce specifics of the products upon approval and when production has started. Duyuru • May 19
Pascal Biosciences Inc.'s Shares Will Be De-Listed from the TSX.V At the Close of the Market on May 23, 2023 Shareholders of Pascal Biosciences Inc. owning 56% of the issued shares of the company have approved the reorganization of the company, including delisting from the TSX Venture Exchange. Details of the reorganization were disclosed in prior releases dated Dec. 9, 2022, and Feb. 15, 2023. At the request of the Company, the Shares will be de-listed from the TSX.V at the close of the market on May 23, 2023. Immediately thereafter: (i) the Company's name will be changed to Nevis Brands Inc., (ii) the Shares will consolidate on the basis of one new share for five old shares, and (iii) the Company's board of directors and the CEO will change. A news release will be issued the next day providing details about the new directors and the CEO. The Company has received a conditional listing letter dated April 26, 2023 from the Canadian Securities Exchange (the "CSE"). That letter requires the Company's reorganization to complete on the day the Shares are listed on the CSE (the "Listing Date"). On the Listing Date, a private placement of $2,000,000 (the "Private Placement") and the acquisition of THC Essentials (the Acquisition") are required to close as well as issuing Shares for debt, which will complete the reorganization. Completion of the transactions disclosed in this press release are subject to a number of conditions, including closing the Private Placement and the Acquisition. There can be no assurance that the Transaction will be completed as proposed or at all. Investors are cautioned that, except as disclosed in further news releases or the CSE form 2AListing Statement, still to be finalized, any information released or received with respect to the transactions may not be accurate or complete and should not be relied upon. The Shares of the Company have been halted since the first week of December 2022. Board Change • Apr 27
High number of new and inexperienced directors There are 7 new directors who have joined the board in the last 3 years. The company's board is composed of: 7 new directors. 4 experienced directors. No highly experienced directors. Independent Director Terry Pearson is the most experienced director on the board, commencing their role in 2014. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors. Duyuru • Apr 22
Pascal Biosciences Inc. To File Patent For COVID-19 Antiviral Activity With CBD Pascal Biosciences Inc. was the first to report cannabinoids can kill SARS-CoV-2, the virus that causes Covid-19. Pascal filed an international patent covering this work prior to the press release in July 2020, and now it is clear that Pascal was the first to file to protect this discovery. This means that Pascal holds the rights to therapeutic treatment of Covid-19 by cannabinoids, particularly CBD. Pascal scientists have replicated this work in four different antiviral assays and have also shown that CBD has an antiviral activity similar to remdesivir, a Gilead Sciences drug approved for treatment of Covid-19. Furthermore, Pascal's discovery has been confirmed and extended by several academic groups. A lab at the University of Chicago has recently shown that CBD suppressed infection in mice, and also that epilepsy patients treated with CBD have significantly lower rates of SARS-CoV-2 infection than matched patients. A separate academic study suggests that CBD viral blockade is not variant specific, so CBD treatment should be beneficial as the virus mutates during the pandemic. There are currently at least four clinical trials testing CBD in Covid-19 patients. While Pascal is not involved in those studies, the rights to treat patients would be covered by Pascal's patent if CBD is approved by regulatory officials. After 18 months, patent submissions become public information. The absence of other patents predating Pascal's submission date confirm that Pascal was the first to file and protect this discovery. Duyuru • Jun 09
Pascal Biosciences Inc. Receives Grant of USD 343,750 from National Cancer Institute of the US National Institutes of Health for Leukemia Program Pascal Biosciences Inc. announced that it has been awarded a grant of USD 343,750 from the National Cancer Institute of the US National Institutes of Health. This two-year award will fund development of the company’s antibody drug for Acute Lymphoblastic Leukemia (ALL), which is the most common childhood leukemia. The company is the first to advance an antibody targeting the highly leukemia-specific protein, VpreB, for treating ALL. The company’s drug will be eligible for orphan drug designation, which can enable financial incentives and a seven year marketing exclusivity. The company has filed for patent protection for its ALL treatment. While the number of patients with ALL is relatively small, the market potential for the company’s drug could be significant. Executive Departure • May 01
CFO & Corporate Secretary has left the company On the 30th of April, Judith Dalling's tenure as CFO & Corporate Secretary ended after 7.9 years in the role. We don't have any record of a personal shareholding under Judith's name. A total of 3 executives have left over the last 12 months. Duyuru • Mar 18
Pascal Biosciences Inc. announced that it has received CAD 0.75 million in funding On March 17, 2021, Pascal Biosciences Inc. (TSXV:PAS) closed the transaction. The company issued 1,900,000 units for gross proceeds of CAD 190,000 in its second tranche. The company paid a finders fees of CAD 1,365 in the second trache. Certain directors and officers of the Company acquired 1,255,000 Units under the Private Placement. The transaction is subject to final acceptance by the TSX Venture Exchange upon filing of final documents. Duyuru • Nov 03
Pascal Biosciences Inc. announced that it expects to receive CAD 1 million in funding Pascal Biosciences Inc. (TSXV:PAS) announced a non-brokered private placement of up to 5,000,000 units at a price of CAD 0.20 per unit for gross proceeds of CAD 1,000,000 on November 2, 2020. The transaction may involve participation from certain directors and officers. Each unit will consist of one common share and one common share purchase warrant. Each warrant entitles the holder to purchase one additional common share at a price of CAD 0.35 per share for a period of 12 months from the date of closing, subject to an exercise acceleration clause. Under the exercise acceleration clause, which the company may exercise once the units are free of resale restrictions and if the company’s shares are trading at or above a volume weighted average price of CAD 0.50 for 10 consecutive trading days, the warrants will expire upon 30 days from the date the company provides notice in writing to the warrant holders. The securities to be issued under the transaction will be subject to a four-month hold period and subject to the acceptance of the TSX Venture Exchange. Duyuru • Sep 29
SORSE Technology entered into a non-binding term sheet to acquire Pascal Biosciences US, Inc. from Pascal Biosciences Inc. (TSXV:PAS) for $9.5 million. SORSE Technology entered into a non-binding term sheet to acquire Pascal Biosciences US, Inc. from Pascal Biosciences Inc. (TSXV:PAS) for $9.5 million on March 10, 2020. Under the transaction, SORSE Technology will issue its shares as consideration for the acquisition. As additional consideration for the sale, SORSE Technology will permit Pascal Biosciences US, Inc.'s employees to support Pascal's retained intellectual property and scientific programs at no additional cost to Pascal Biosciences Inc., in accordance with a work program to be determined in the definitive agreement. Upon closing of the transaction, Pascal Biosciences Inc. will hold at least 15.8% of the outstanding shares of SORSE Technology. Upon closing of the transaction, SORSE Technology will invest an additional $0.25 million in Pascal Biosciences Inc. on a private placement basis. Pursuant to the term sheet, Pascal Biosciences Inc. has agreed to exclusively negotiate the terms of the transaction with SORSE Technology until May 27, 2020. If entered into, the definitive agreement, and any ancillary transaction agreements, will contain representations and warranties, conditions relating to regulatory approvals, TSX Venture Exchange approvals and any required shareholder approvals, and other terms as are customary in comparable transactions of this nature. In addition, if transaction results in the sale of more than 50% of Pascal Biosciences Inc.’s assets, business or undertaking, as an additional condition to closing of the transaction, Pascal Biosciences Inc. will be required to obtain approval from its shareholders in accordance with Policy 5.3 of the TSX Venture Exchange. Duyuru • Sep 26
Pascal Biosciences Inc. Confirms an Earlier Report Certain Cannabinoids Block Replication of SARS-CoV-2 Pascal Biosciences Inc. announced the Company has confirmed an earlier report that certain cannabinoids block replication of SARS-CoV-2, the coronavirus that causes COVID-19. Four different laboratories have now experimentally verified the antiviral activity of a cannabinoid. In addition, several cannabinoids have been tested, and the optimal compound has been chosen for further study. The best cannabinoid had potency similar to remdesivir in two different assays. Remdesivir is an approved drug from Gilead that improves recovery time for COVID-19 patients. The four laboratories testing Pascal compounds are Southern Research, Institut Pasteur Korea, and two independent University of Washington academic groups. Three of the laboratories used the African green monkey kidney epithelial cell line, Vero E6, a common model system for testing coronaviral infectivity. In all three of these assays, the lead cannabinoid had good potency (antiviral activity in the range of 1 to 10 micromolar, similar to remdesivir). The fourth laboratory measured the antiviral effect on SARS-CoV-
2 on the human lung cell line, Calu-3, and found the cannabinoid to be nearly 100-fold more potent in inhibiting virus-mediated cell death than it was in the Vero E6 experiments. This is an important observation, as the human respiratory tract represents the first point of contact with the virus. Pascal scientists are very encouraged by the reproducibility of the cannabinoid's protective activity in different experimental systems and in different laboratories. These results support rationale for testing in animal models of COVID-19, both in single agent and in combination with other antiviral compounds such as remdesivir, and Pascal is currently planning these experiments. There are many efforts to create a vaccine or therapeutic drug for SARS-CoV-2 infection. Pascal's cannabinoid has the potential to limit the severity and progression of the disease. Typically, multiple drugs
are required to provide effective antiviral therapy. For example, other viral diseases such as HIV and Hepatitis C require two or three drugs for effective treatment. The novel discovery by Pascal scientists suggests a cannabinoid may well become an essential component of an effective drug cocktail for the treatment of COVID-19. The Company is not making any express or implied claims that its product has the ability to eliminate, cure or contain the Covid-19 (or SARS-2 Coronavirus) at this time. Duyuru • Sep 16
Pascal Biosciences Inc. and SoRSE Technology Corporation Enters into a Collaborative Research Agreement to Advance Pascal’s PAS-393 into Clinical Testing Pascal Biosciences Inc. and SoRSE Technology Corporation have entered into a Collaborative Research Agreement to advance Pascal’s PAS-393 into clinical testing. Pascal and SoRSE will share their respective technologies to test the cannabinoid PAS-393 in human volunteers, enabling testing of cancer patients treated with checkpoint inhibitors. As initially announced last March, this partnership leverages SoRSE’s formulation technology with Pascal’s proprietary cannabinoid programs for clinical trials. This will be the first pharmaceutical use of the novel formulation technology developed by SoRSE. The agreement will include Pascal’s intellectual property, which covers the use of cannabinoids in cancer patients treated with checkpoint inhibitors. SoRSE currently sells and licenses a proprietary water-soluble cannabinoid emulsion technology (patent-pending) that enables increased bioavailability, accurate dosing, and more than 12 months’ shelf stability. Pascal and SoRSE scientists will optimize a cannabinoid formulation for human subjects and will then test the formulated PAS-393 in volunteers. SoRSE will provide $750,000 in research funding to Pascal throughout the 15-month collaboration and will pay for related research expenditures. Following characterization of safety and pharmacology in a Phase 1a clinical trial, Pascal and SoRSE may elect to continue clinical development as equal partners in a Phase 1b cancer trial in combination with a checkpoint inhibitor. Dr. Gray will present scientific data this September 15th at the 3rd Annual International Cannabinoid-Derived Pharmaceutical Conference occurring in Boston, MA; the topic of his presentation is “Identifying and Validating Mechanism of Action In vivo/vitro.” SoRSE intends to collaborate with other researchers and product developers to study cannabinoids in other medical applications. Pascal will continue to pursue other non-cancer indications for PAS-393. 
